16-18 July 2018 | Boston

 

Day One
Tuesday, July 17th 2018

Day Two
Wednesday, July 18th 2018

Advancing Preclinical Modeling to Enhance the Translational Success of Anti-Cancer Therapies

Developing Checkpoint Target Humanized Models for Pre-clinical Efficacy Assessment

09.00
Pre-clinical Modeling of Immune Responses to Cancer: From Bench- Side to Clinical Outcomes

09.30
Patient-Derived Tumor Xenografts in Humanized NSG-SGM3 Mice: A New Immuno-Oncology Platform

  • Rick Huntress Director - Business Development, Clinical & In Vivo Services Business Development, Clinical & In Vivo Service, The Jackson Laboratory

10.00
Speed Networking and Morning Refreshments

Modelling Sensitivity and Resistance, and Examining Strategies to Overcome Them

11.00 Myeloid Derived Suppressor Cells In Tumor Microenvironment

Dmitry Gabrilovich, Professor & Program Leader – Translational Tumor Immunology Program, The Wistar Institute

Leveraging the TME in Anti-Cancer Therapies

11.00 Understanding the Role of Stromal Cells in the Tumor Microenvironment and the Effect of Cross-Talk with Immune Cells

Zhao Chen, Investigator III, Genomics Institute of the Novartis Research Foundation (GNF)